Protara Therapeutics (TARA) Other Non-Current Assets (2014 - 2026)
Protara Therapeutics (TARA) recorded quarterly Other Non-Current Assets of $6.0 million in Q1 2026, up 29800.0% quarter-over-quarter from $20000.0 in Q4 2025, and up 702.68% on a YoY basis from $745000.0 in Q1 2025.
Protara Therapeutics (TARA) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Protara Therapeutics' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $6.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 702.68% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (up 702.68% YoY), while the FY2025 annual figure was $20000.0, down 99.39% from the prior year.
- Other Non-Current Assets was $6.0 million for Q1 2026 at Protara Therapeutics, up from $20000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $6.0 million in Q1 2026 to a low of $20000.0 in Q4 2025.
- Historically, Other Non-Current Assets has averaged $1.1 million across 5 years, with a median of $745000.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets surged 1474.0% in 2022, then tumbled 99.39% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $644000.0 in 2022, then rose by 15.68% to $745000.0 in 2023, then jumped by 339.19% to $3.3 million in 2024, then sank by 99.39% to $20000.0 in 2025, then surged by 29800.0% to $6.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $6.0 million (Q1 2026), $20000.0 (Q4 2025), and $21000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Protara Therapeutics | 216.35 Mn | 216.35 Mn | - | 5.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.98 Mn |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 745,000.00 |
| Mar 31, 2025 | 745,000.00 |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 745,000.00 |
| Jun 30, 2024 | 745,000.00 |
| Mar 31, 2024 | 745,000.00 |
| Dec 31, 2023 | 745,000.00 |
| Sep 30, 2023 | 745,000.00 |
| Jun 30, 2023 | 745,000.00 |
| Mar 31, 2023 | 745,000.00 |
| Dec 31, 2022 | 644,000.00 |
| Sep 30, 2022 | 745,000.00 |
| Jun 30, 2022 | 811,000.00 |
| Mar 31, 2022 | 787,000.00 |
| Dec 31, 2021 | 865,000.00 |
| Sep 30, 2021 | 946,000.00 |
| Jun 30, 2021 | 1.02 Mn |